Precigen, Inc.
NASDAQ:PGENBiotechnology
Healthcare
$4.16 -2.08%
-$0.10 today
- Market cap
- $1.49B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
52W Low $1.39High $5.47
Volume 4.37M
Average 4.72M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$87.83M
FY 2025 · Annual
Investing Cash Flow
-$1.53M
FY 2025 · Annual
Financing Cash Flow
$90.05M
FY 2025 · Annual
-18.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| Deferred Income Tax | (167K) | (150K) | (479K) | (1.8M) | 0 |
| Stock-Based Compensation | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M |
| Change in Working Capital | (804K) | (35.7M) | 17.07M | 4.52M | 6.62M |
| Accounts Receivables | (6.56M) | (13.51M) | 12.23M | 414K | (3.2M) |
| Inventory | (1.9M) | 2.34M | 0 | 0 | (9.21M) |
| Accounts Payables | 420K | 379K | (2.42M) | 1.55M | 8.77M |
| Other Working Capital | 7.24M | (24.91M) | 7.26M | 2.56M | 10.26M |
| Other Non-Cash Items | 9.7M | (78.48M) | (4.17M) | 41.34M | 142.12M |
| Operating Cash Flow | (55.77M) | (65.05M) | (66.93M) | (68.17M) | (87.83M) |
| Capital Expenditures | (7.25M) | (4.92M) | (1.54M) | (8.58M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (174.22M) | 0 | (185.03M) | (187.21M) | (208.01M) |
| Sales of Investments | 100.17M | 68.44M | 183.38M | 175.02M | 208.47M |
| Other Investing Activities | 6.76M | 162.9M | 98K | 60K | 0 |
| Investing Cash Flow | (74.54M) | 226.42M | (3.09M) | (20.71M) | (1.54M) |
| Debt Repayment | (466K) | (155.29M) | (43.22M) | 0 | 92.82M |
| Common Stock Issued | 121.05M | 0 | 72.81M | 31.24M | 310K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 608K | 1K | 0 | 346K | (3.08M) |
| Financing Cash Flow | 121.19M | (155.29M) | 29.59M | 110.58M | 90.05M |
| Effect of Forex Changes | 217K | (827K) | (320K) | (27K) | 35K |
| Net Change in Cash | (8.91M) | 5.25M | (40.75M) | 21.67M | 717K |
| Free Cash Flow | (63.02M) | (69.97M) | (68.47M) | (76.76M) | (89.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$250.6M
+ D&A$3.2M
+ Stock-Based Comp$10.9M
+ Deferred Tax$0
+ Working Capital$6.6M
+ Other Non-Cash$142.1M
= Operating Cash Flow-$87.8M
- Capex-$2.0M
= Free Cash Flow-$89.8M
Analysis
FY2025 free cash flow is -$89.8M. FCF conversion is 35.8% of net income. Operating cash flow was -$87.8M, with capex of -$2.0M. The largest bridge item is Other Non-Cash at $142.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 |
Does PGEN generate free cash flow?
Precigen, Inc. (PGEN) generated -$89.83M of free cash flow in fiscal 2025.
How much operating cash flow does PGEN produce?
Operating cash flow was -$87.83M, before capital expenditures of $2.00M.
Continue the stock analysis
Jump to another research area for this company.